Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis
- PMID: 24290431
- PMCID: PMC4410183
- DOI: 10.1016/j.jaad.2013.10.010
Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis
Abstract
Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed.
Keywords: AAD; AD; ADHD; American Academy of Dermatology; CDLQI; Children's Dermatology Life Quality Index; DFI; DLQI; Dermatitis Family Impact; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; FLG; GREAT; Global Resource for Eczema Trials; IGA; IL; ISAAC; IgE; International Study of Asthma and Allergies in Childhood; Investigator's Global Assessment; MDC; POEM; Patient-Oriented Eczema Measure; SASSAD; SCORAD; SCORing Atopic Dermatitis; SORT; Six Area, Six Sign Atopic Dermatitis; TARC; TISS; Three-Item Severity Scale; UK; United Kingdom; assessment scales; atopic dermatitis; attention deficit hyperactivity disorder; biomarkers; clinical associations; criteria; diagnosis; filaggrin; immunoglobulin E; interleukin; macrophage-derived chemoattractant; risk factors; strength of recommendation taxonomy; thymus and activation-regulated chemokine.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Similar articles
-
Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: A validation study.Ann Allergy Asthma Immunol. 2020 Jul;125(1):78-83. doi: 10.1016/j.anai.2020.03.006. Epub 2020 Mar 18. Ann Allergy Asthma Immunol. 2020. PMID: 32199977
-
Validation of five patient-reported outcomes for atopic dermatitis severity in adults.Br J Dermatol. 2020 Jan;182(1):104-111. doi: 10.1111/bjd.18002. Epub 2019 Jul 24. Br J Dermatol. 2020. PMID: 30972740
-
Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life.Dermatology. 2014;229(3):248-55. doi: 10.1159/000365075. Epub 2014 Aug 29. Dermatology. 2014. PMID: 25196258
-
Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.Curr Med Res Opin. 2021 Aug;37(8):1295-1301. doi: 10.1080/03007995.2021.1933929. Epub 2021 Jun 11. Curr Med Res Opin. 2021. PMID: 34027753
-
Useful tools for the management of atopic dermatitis.Am J Clin Dermatol. 2009;10(5):287-300. doi: 10.2165/11310760-000000000-00000. Am J Clin Dermatol. 2009. PMID: 19658441 Review.
Cited by
-
Increased Expression of Interleukin-12 in Lesional Skin of Atopic Dermatitis Patients with Psoriasiform Features on Histopathology: An Immunohistochemical Study.Ann Dermatol. 2020 Feb;32(1):31-37. doi: 10.5021/ad.2020.32.1.31. Epub 2019 Dec 27. Ann Dermatol. 2020. PMID: 33911706 Free PMC article.
-
IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis.Clin Transl Allergy. 2020 Aug 3;10:34. doi: 10.1186/s13601-020-00338-7. eCollection 2020. Clin Transl Allergy. 2020. PMID: 32774842 Free PMC article. Review.
-
Distinct Immunophenotypic Features in Patients Affected by 22q11.2 Deletion Syndrome with Immune Dysregulation and Infectious Phenotype.J Clin Med. 2023 Dec 8;12(24):7579. doi: 10.3390/jcm12247579. J Clin Med. 2023. PMID: 38137647 Free PMC article.
-
The therapeutic effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on chemically induced atopic dermatitis.Sci Rep. 2024 Oct 8;14(1):23402. doi: 10.1038/s41598-024-73951-2. Sci Rep. 2024. PMID: 39379428 Free PMC article.
-
The future of biologics: applications for food allergy.J Allergy Clin Immunol. 2015 Feb;135(2):312-23. doi: 10.1016/j.jaci.2014.12.1908. J Allergy Clin Immunol. 2015. PMID: 25662303 Free PMC article. Review.
References
-
- Nankervis H, Maplethorpe A, Williams HC. Mapping randomized controlled trials of treatments for eczema--the GREAT database (the Global Resource of EczemA Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010) BMC dermatology. 2011;11:10. - PMC - PubMed
-
- Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”. J Am Acad Dermatol. 2004;50:391–404. - PubMed
-
- Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26:1176–1193. - PubMed
-
- Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045–1060. - PubMed
-
- Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131:295–299. e1–27. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous